CeNeRx BioPharma, based in Cary, North Carolina, is a specialty biopharmaceutical company that is developing a portfolio of clinical-stage therapeutics for the treatment of depression, anxiety, and epilepsy, as well as a preclinical pipeline of selective cannabinoid compounds for pain, glaucoma, and spasticity. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase-A used for the treatment of mood, anxiety, and somatic disorders. CeNeRx is dedicated to addressing diseases related to neurotransmitters, such as anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, Parkinson's, and Alzheimer's diseases.